Nifty
Sensex
:
:
11504.95
38845.82
-11.15 (-0.10%)
-134.03 (-0.34%)

Pharmaceuticals & Drugs

Rating :
50/99

BSE: 532660 | NSE: VIVIMEDLAB

20.30
18-Sep-2020
  • Open
  • High
  • Low
  • Previous Close
  •  20.30
  •  20.60
  •  20.10
  •  19.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  266041
  •  54.13
  •  23.35
  •  6.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 168.73
  • N/A
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,028.14
  • N/A
  • 0.35

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 32.79%
  • 6.96%
  • 38.77%
  • FII
  • DII
  • Others
  • 3.56%
  • 0.12%
  • 17.80%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.37
  • -0.96
  • -3.46

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.13
  • -5.31
  • -16.02

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.35
  • -4.45
  • -35.52

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.05
  • 4.08
  • 2.97

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 0.86
  • 0.76
  • 0.40

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.62
  • 7.26
  • 7.97

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
322.79
344.21
-6.22%
235.82
348.08
-32.25%
197.70
243.93
-18.95%
281.07
364.62
-22.91%
Expenses
276.21
303.11
-8.87%
256.48
326.69
-21.49%
206.57
207.18
-0.29%
284.53
314.42
-9.51%
EBITDA
46.58
41.10
13.33%
-20.66
21.39
-
-8.87
36.74
-
-3.46
50.20
-
EBIDTM
14.43%
11.94%
-8.76%
6.14%
-4.49%
15.06%
-1.23%
13.77%
Other Income
1.81
1.27
42.52%
2.42
6.10
-60.33%
2.09
6.31
-66.88%
2.48
5.04
-50.79%
Interest
14.88
12.11
22.87%
14.71
12.83
14.65%
16.48
17.56
-6.15%
15.59
17.59
-11.37%
Depreciation
17.29
16.95
2.01%
17.48
16.05
8.91%
15.62
15.29
2.16%
16.90
19.58
-13.69%
PBT
16.22
13.31
21.86%
-50.44
-1.40
-
-38.88
10.21
-
-33.47
18.07
-
Tax
3.38
3.16
6.96%
10.40
-1.41
-
-6.80
-0.63
-
-7.12
-0.21
-
PAT
12.84
10.15
26.50%
-60.84
0.01
-
-32.07
10.84
-
-26.35
18.28
-
PATM
3.98%
2.95%
-25.80%
0.00%
-16.22%
4.44%
-9.38%
5.01%
EPS
1.55
1.22
27.05%
-7.34
0.00
-
-3.87
1.31
-
-3.18
2.21
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
1,037.38
1,315.17
1,185.66
1,461.91
1,345.63
1,380.10
1,350.83
1,108.80
668.31
416.00
343.49
Net Sales Growth
-20.25%
10.92%
-18.90%
8.64%
-2.50%
2.17%
21.83%
65.91%
60.65%
21.11%
 
Cost Of Goods Sold
439.09
518.40
479.67
536.28
624.05
646.23
656.33
513.27
337.39
236.97
203.49
Gross Profit
598.29
796.77
705.99
925.63
721.58
733.88
694.51
595.52
330.93
179.03
140.00
GP Margin
57.67%
60.58%
59.54%
63.32%
53.62%
53.18%
51.41%
53.71%
49.52%
43.04%
40.76%
Total Expenditure
1,023.79
1,146.24
984.93
1,057.46
1,122.68
1,158.21
1,166.29
928.00
538.02
329.44
279.13
Power & Fuel Cost
-
42.77
34.73
34.78
38.26
46.70
51.39
44.06
22.33
11.08
8.28
% Of Sales
-
3.25%
2.93%
2.38%
2.84%
3.38%
3.80%
3.97%
3.34%
2.66%
2.41%
Employee Cost
-
241.76
197.78
189.98
176.94
184.43
162.66
50.33
32.19
19.97
22.07
% Of Sales
-
18.38%
16.68%
13.00%
13.15%
13.36%
12.04%
4.54%
4.82%
4.80%
6.43%
Manufacturing Exp.
-
217.39
176.69
175.06
167.31
179.26
182.37
230.50
91.61
32.06
19.82
% Of Sales
-
16.53%
14.90%
11.97%
12.43%
12.99%
13.50%
20.79%
13.71%
7.71%
5.77%
General & Admin Exp.
-
111.52
78.75
93.93
95.26
76.30
86.64
69.34
31.42
15.96
15.29
% Of Sales
-
8.48%
6.64%
6.43%
7.08%
5.53%
6.41%
6.25%
4.70%
3.84%
4.45%
Selling & Distn. Exp.
-
14.41
16.66
15.39
20.86
25.29
26.91
20.50
23.09
11.26
9.32
% Of Sales
-
1.10%
1.41%
1.05%
1.55%
1.83%
1.99%
1.85%
3.45%
2.71%
2.71%
Miscellaneous Exp.
-
0.00
0.65
12.03
0.00
0.00
0.00
0.00
0.00
2.14
9.32
% Of Sales
-
0%
0.05%
0.82%
0%
0%
0%
0%
0%
0.51%
0.25%
EBITDA
13.59
168.93
200.73
404.45
222.95
221.89
184.54
180.80
130.29
86.56
64.36
EBITDA Margin
1.31%
12.84%
16.93%
27.67%
16.57%
16.08%
13.66%
16.31%
19.50%
20.81%
18.74%
Other Income
8.80
33.97
23.76
8.09
23.63
8.02
35.90
26.33
2.68
1.00
6.84
Interest
61.66
70.06
82.35
67.79
85.26
86.20
67.46
50.44
28.37
22.10
22.82
Depreciation
67.29
66.79
56.42
58.28
61.39
66.18
66.12
58.81
26.79
10.20
8.73
PBT
-106.57
66.05
85.71
286.48
99.93
77.54
86.86
97.88
77.82
55.26
39.65
Tax
-0.14
8.68
9.62
72.50
16.26
5.49
20.47
14.29
14.68
6.43
8.63
Tax Rate
0.13%
13.14%
11.22%
25.31%
16.27%
7.08%
23.57%
14.60%
18.86%
11.64%
21.77%
PAT
-106.42
57.37
77.94
213.97
83.67
72.05
66.39
83.58
63.14
48.83
31.01
PAT before Minority Interest
-106.42
57.37
76.09
213.97
83.67
72.05
66.39
83.58
63.14
48.83
31.01
Minority Interest
0.00
0.00
1.85
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-10.26%
4.36%
6.57%
14.64%
6.22%
5.22%
4.91%
7.54%
9.45%
11.74%
9.03%
PAT Growth
-370.93%
-26.39%
-63.57%
155.73%
16.13%
8.53%
-20.57%
32.37%
29.31%
57.47%
 
EPS
-12.84
6.92
9.40
25.81
10.09
8.69
8.01
10.08
7.62
5.89
3.74

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
943.79
1,226.40
734.21
585.15
559.24
560.36
509.14
474.79
196.71
144.86
Share Capital
341.73
341.73
16.20
80.15
80.15
80.15
80.01
144.88
10.16
9.96
Total Reserves
602.07
884.67
718.01
505.00
479.09
477.84
426.77
327.54
177.68
129.94
Non-Current Liabilities
489.65
356.86
503.86
561.11
538.36
532.58
449.68
360.72
148.25
251.48
Secured Loans
369.08
275.90
396.25
206.75
436.44
378.81
255.19
258.03
131.90
234.55
Unsecured Loans
55.72
49.30
57.07
50.52
46.94
40.92
41.73
53.35
0.00
0.74
Long Term Provisions
9.21
7.03
2.19
3.57
3.17
5.16
1.47
1.06
1.69
0.00
Current Liabilities
888.93
790.23
817.39
897.41
800.86
744.42
610.73
463.69
242.44
59.38
Trade Payables
294.42
201.99
178.59
166.74
188.71
190.49
166.28
156.86
44.06
42.35
Other Current Liabilities
227.11
147.64
179.92
285.85
176.38
138.78
116.10
40.79
4.68
0.04
Short Term Borrowings
332.30
385.16
381.47
407.76
389.38
375.43
301.13
232.82
175.08
0.00
Short Term Provisions
35.10
55.43
77.41
37.06
46.39
39.71
27.22
33.21
18.61
17.00
Total Liabilities
2,322.37
2,385.77
2,055.46
2,043.67
1,898.46
1,837.36
1,569.55
1,299.20
587.40
455.72
Net Block
964.92
1,035.36
878.90
814.17
813.47
807.92
709.04
595.35
264.29
254.72
Gross Block
1,156.58
1,128.64
915.77
1,663.33
1,599.11
1,526.04
1,329.52
1,167.48
812.71
289.11
Accumulated Depreciation
191.65
93.29
36.87
849.16
785.64
718.12
620.49
572.13
548.42
34.39
Non Current Assets
1,091.77
1,103.83
961.04
911.03
906.45
846.28
736.20
604.41
266.01
255.86
Capital Work in Progress
122.31
65.27
76.13
94.17
90.28
38.12
26.92
8.37
1.73
1.14
Non Current Investment
2.51
2.70
2.71
2.69
2.70
0.24
0.24
0.70
0.00
0.00
Long Term Loans & Adv.
1.52
0.00
2.81
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Non Current Assets
0.50
0.50
0.50
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
1,230.61
1,281.94
1,094.42
1,132.60
991.96
970.90
815.08
647.14
314.68
194.06
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
563.69
540.17
483.97
490.80
431.43
426.66
340.26
247.88
84.47
79.35
Sundry Debtors
356.11
275.43
200.14
326.24
329.58
347.83
308.23
221.61
127.56
93.86
Cash & Bank
95.30
99.03
55.47
30.96
26.67
34.57
23.96
36.34
11.10
5.62
Other Current Assets
215.51
29.59
22.53
11.73
204.28
161.84
142.64
141.32
91.55
15.23
Short Term Loans & Adv.
184.76
337.73
332.31
272.88
185.21
139.50
119.82
141.09
89.45
15.20
Net Current Assets
341.68
491.71
277.03
235.19
191.10
226.47
204.35
183.45
72.25
134.67
Total Assets
2,322.38
2,385.77
2,055.46
2,043.67
1,898.45
1,837.36
1,569.55
1,299.21
587.39
455.73

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
422.14
21.42
57.96
154.12
140.48
-117.65
90.11
45.17
23.89
55.13
PBT
66.05
85.71
286.48
99.93
77.54
86.86
97.88
77.81
55.26
39.65
Adjustment
134.05
135.90
124.15
101.94
111.32
101.31
80.43
55.16
32.30
30.82
Changes in Working Capital
237.03
-158.14
-315.94
-47.75
-48.38
-305.83
-94.13
-87.81
-63.67
5.89
Cash after chg. in Working capital
437.13
63.48
94.69
154.12
140.48
-117.65
84.18
45.17
23.89
76.36
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-14.99
-42.06
-36.73
0.00
0.00
0.00
5.93
0.00
0.00
0.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-88.87
-163.53
-68.49
-190.42
-106.71
-291.11
-169.59
-424.15
-72.39
-7.13
Net Fixed Assets
-15.53
38.52
-25.51
-6.97
-49.04
-16.56
-128.68
-148.52
-26.78
7.77
Net Investments
64.34
-64.27
142.45
0.00
-2.50
-132.00
-8.38
-83.77
0.09
-0.98
Others
-137.68
-137.78
-185.43
-183.45
-55.17
-142.55
-32.53
-191.86
-45.70
-13.92
Cash from Financing Activity
-337.80
185.66
35.05
40.59
-41.67
419.37
67.10
404.22
53.98
-59.36
Net Cash Inflow / Outflow
-4.53
43.56
24.51
4.29
-7.90
10.62
-12.38
25.24
5.47
-11.35
Opening Cash & Equivalents
99.03
55.47
30.96
26.67
34.57
23.96
36.34
11.10
5.62
16.98
Closing Cash & Equivalent
94.50
99.03
55.47
30.96
26.67
34.57
23.96
36.34
11.10
5.62

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
70.35
104.60
85.93
64.20
61.00
58.36
52.74
42.03
35.45
26.71
ROA
2.44%
3.43%
10.44%
4.25%
3.86%
3.90%
5.83%
6.69%
9.36%
6.87%
ROE
7.95%
9.76%
35.18%
16.50%
14.90%
14.81%
23.34%
26.70%
31.18%
27.74%
ROCE
7.03%
9.04%
21.86%
11.93%
10.91%
11.93%
13.83%
14.29%
17.80%
16.30%
Fixed Asset Turnover
1.15
1.16
1.13
0.82
0.88
0.95
0.89
0.67
0.76
1.26
Receivable days
87.64
73.20
65.71
88.94
89.58
88.63
87.21
95.35
97.13
87.46
Inventory Days
153.18
157.64
121.69
125.08
113.47
103.61
96.80
90.76
71.87
78.89
Payable days
79.66
70.90
60.76
60.42
57.00
57.11
62.91
65.22
47.96
41.69
Cash Conversion Cycle
161.15
159.93
126.64
153.61
146.05
135.14
121.10
120.89
121.04
124.66
Total Debt/Equity
1.05
0.69
1.45
1.63
1.81
1.66
1.36
1.33
1.70
1.77
Interest Cover
1.94
2.04
5.23
2.17
1.90
2.29
2.94
3.74
3.50
2.74

News Update:


  • Vivimed Labs receives export order for supply of Favulous tablets
    6th Aug 2020, 09:00 AM

    Favulous tablets 200 mg is used for the treatment of mild to moderate cases of Covid-19

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.